VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)
A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients
Sponsor: GlaxoSmithKline
This PHASE2/PHASE3 trial investigates Covid19 and is currently completed. GlaxoSmithKline leads this study, which shows 13 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Oct 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Apr 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Vir Biotechnology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .